Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Farxiga Overview 2019: A Member of the Novel Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Class
June 25, 2019 Off

Farxiga Overview 2019: A Member of the Novel Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Class

By BusinessWire

It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy.

Keytruda’s diffuse large Bcell lymphoma market potential  remains limited
June 25, 2019 Off

Keytruda’s diffuse large Bcell lymphoma market potential remains limited

By BusinessWire

Keytruda’s market potential in this indication remains limited due to its approval for primary mediastinal B-cell lymphoma (PMBCL), which only accounts for a small percentage of non-Hodgkin’s lymphoma (NHL) patients.

Tilray Imports Bulk Supply of Medical Cannabis Oil into the United Kingdom
June 25, 2019 Off

Tilray Imports Bulk Supply of Medical Cannabis Oil into the United Kingdom

By BusinessWire

Tilray has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada.

Amring Pharmaceuticals launches two pharmaceutical generics to the US market
June 25, 2019 Off

Amring Pharmaceuticals launches two pharmaceutical generics to the US market

By BusinessWire

Amring Pharmaceuticals, a generic pharmaceutical and ophthalmic medical device company, announced today that it has launched two valued drugs into its generic portfolio and to the U.S. Market.

Poxel, Sumitomo Dainippon Pharma’s  Type 2 Diabetes combo imeglimin/insulin Phase 3 trial meets primary endpoint
June 25, 2019 Off

Poxel, Sumitomo Dainippon Pharma’s Type 2 Diabetes combo imeglimin/insulin Phase 3 trial meets primary endpoint

By BusinessWire

Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile

Ipsen nets FDA approval for new pre-filled syringe for Somatuline Depot
June 25, 2019 Off

Ipsen nets FDA approval for new pre-filled syringe for Somatuline Depot

By BusinessWire

FDA has approved Ipsen’s new pre-filled syringe for Somatuline
Depot.

Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis
June 25, 2019 Off

Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis

By BusinessWire

Dermira set to receive an option exercise fee of $50 million and additional potential milestone payments and royalties

Longboat Clinical Launch Patient CONNECT to Streamline Patient Recruitment Process
June 25, 2019 Off

Longboat Clinical Launch Patient CONNECT to Streamline Patient Recruitment Process

By BusinessWire

Longboat Clinical, the clinical technology company specializing in site and patient engagement platforms, today announced the release of Patient CONNECT, a unique solution to streamline patient recruitment into clinical trials and provide much sought-after insights to drug development teams.

June 25, 2019 Off

Inhalers Medical Devices Pipeline Assessment

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Inhalers – Medical Devices Pipeline Assessment, 2019” report has been added to ResearchAndMarkets.com’s offering. The Medical Devices sector…

June 25, 2019 Off

Patient Engagement in R&D: Still a Challenge for Pharma Companies

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Patient Engagement in R&D: Still a Challenge” report has been added to ResearchAndMarkets.com’s offering. The pharmaceutical industry has…

Posts pagination

Previous 1 … 3,050 3,051 3,052 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine